Journal du sang et de la lymphe

Aim: To demonstrate the effectiveness of a two months treatment with Mesoglycan after superficial vein surgery in the prevention of superficial vein thrombosis (SVT) and deep vein thrombosis (DVT).
Methods: From January 2014 to April 2015, all patients underwent superficial vein surgery were enrolled and analyzed. Clinical examination through CEAP class identification, Venous Clinical Severity Score (VCSS), and color Duplex ultrasound scanning (CDUS) were performed before treatment, two days post-operatively and at the 2 month follow-up time. Prophylaxis with heparin was given for 1 week after treatment. Mesoglycan 50 mg tablet BID was continued for 2 months. Primary endpoint was Mesoglycan side effect rate. Secondary endpoints were postoperative deep and/or superficial vein thrombosis (DVT and SVT, respectively), endovenous heat induced thrombosis (EHIT) after laser treatment and recanalization/recurrence rate.
Results: 381 venous interventions in 334 consecutive patients were performed. After exclusion of 18 patients, 363 veins were treated in 361 enrolled patients. Female were 242 (76.6%), mean age was 52 years and mean BMI was 25.2 kg/m². Sixty patients had a history of venous thrombosis (18.9%); 17 had thrombophilia (5.3%). CEAP classification were C2 130 (36.1%), C3 138 (38.2%), C4 77 (21.3%), C5 7 (1.9%) and C6 9 (2.5%) patients. Surgical techniques performed were endovenous laser ablation, sclerotherapy, crossectomy, perforator ligation and/or phlebectomies. All patients enrolled complete the Mesoglycan 2-months therapy. Mesoglycan side effects were referred in 4 patients (1.2%).
At the 2 days FU, CDUS evidenced pathological conditions in 3 cases (0.8%): 1 contralateral SVT, 1 EHIT of the great saphenous vein, and 1 ipsilateral SVT associated to a perforator vein thrombosis. No deep venous thrombosis were documented at the 2 months FU.
Conclusion: Mesoglycan is a safe and well tolerated therapy in patients undergoing venous intervention.

Throughout the world, the most commonly observed cancer in women is breast cancer. Low serum adiponectin levels are positively associated with breast cancer, so it is treated as a breast cancer biomarker. The report focuses the association of adiponectin with age, body mass index, and other breast cancer biomarkers. It is derived herein that mean adiponectin is negatively associated with Age (P=0.0006), Body mass index (BMI) (P<0.0001), Resistin (P=0.0237), while it is positively associated with interaction effects Age*BMI (P=0.0017) and BMI*Resistin (P=0.0615). Some partially significant effects such as Leptin (mean model) and Age (variance model) are also included in the model as confounder (known in Epidemiology). Adiponectin is higher for younger women with low body mass index and low resistin levels, and it is not associated with serum glucose and insulin levels.